Wed, Dec 24, 2014, 9:47 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • Dooper55 Dooper55 Jul 18, 2012 7:41 AM Flag

    Preclinical schizophrenia studies completed

    July 18, 2012, 7:00 a.m. EDT

    Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway

    Omeros Has Notified FDA of Intent to Submit Investigational New Drug Application this Quarter --


    SEATTLE, July 18, 2012 /PRNewswire via COMTEX/ -- Omeros Corporation /quotes/zigman/109048/quotes/nls/omer OMER -6.07% today reported that OMS824, the lead compound in the Company's phosphodiesterase 10 (PDE10) program for schizophrenia, has successfully completed all of the preclinical studies that Omeros expects will be necessary for the drug's planned Investigational New Drug Application (IND). OMS824 selectively inhibits PDE10, which is an enzyme expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease.

    With these positive preclinical data, Omeros confirmed with the U.S. Food and Drug Administration (FDA) the Company's intent to submit an IND for OMS824 during the current quarter. Following IND submission, Omeros is required to wait 30 days before enrolling patients into clinical trials to allow the FDA to review the IND to assure that OMS824 will not subject clinical trial patients to unreasonable risks. Omeros believes that the findings observed in the preclinical toxicology studies of OMS824 do not suggest any unreasonable safety risk to humans. Accordingly, the Company is preparing to begin enrolling patients in a Phase 1 dose-ranging clinical trial following the end of the required 30-day waiting period.

    "Omeros' PDE10 program is on track to report Phase 1 clinical trial data this year," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "Our two Phase 3 programs also remain on schedule, and we expect to read out data later this year from our ongoing trials evaluating OMS302 in lens replacement surgery and OMS103HP in arthroscopic meniscectomy procedures. We have already begun building the NDA for OMS302, which we plan to submit early next year. Our other programs are also advancing nicely, and we anticipate that a number of them will be ready to enter the clinic next year as well."

    About Omeros' PDE10 ProgramPDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition, including schizophrenia and Huntington's disease. Cognitive dysfunction occurs early in these diseases and is responsible for substantial disability. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders, including schizophrenia where OMS824 could also have a beneficial effect on the positive and negative symptoms of the disease. Omeros' PDE10 program has been funded by The Stanley Medical Research Institute against milestones.

    About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ...hooray!!!...now just gotta sit back and wait 6-7 years and a half dozen of MORE secondary offerings to get through phase 3 and you MIGHT have yourself a blockbuster drug!...and what was it that Garth said: "Yeah, and monkeys might fly out of my butt."...HAW, HAW, HAW!!!!...

 
OMER
22.09+0.48(+2.22%)Dec 24 12:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.